| Name | Title | Contact Details |
|---|---|---|
Sarah Whipple |
VP, Legal and Chief Compliance Officer | Profile |
Molly Shea |
Head of Regulatory Affairs | Profile |
Henry Gu |
Vice President, Chief Intellectual Property Counsel | Profile |
Andrea Paul |
Vice President, Legal - Corporate and Securities | Profile |
Laura Graham |
Director, Corporate Counsel | Profile |
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
Zalicus is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.